Antibody and complement levels in patients with hypersplenism associated with cirrhotic portal hypertension and therapeutic principles

Kun Zhang, Min Zeng, Ye-Juan Li, Hong-Fei Wu, Jin-Cai Wu, Zhen-Sheng Zhang, Jin-Fang Zheng, Yun-Fu Lv

Kun Zhang, Min Zeng, Department of Geriatric Center, Hainan General Hospital, Haikou 570311, Hainan Province, China

Ye-Juan Li, Reproductive Medicine Center, Maternal and Child Health Care Hospital of Hainan Province, Haikou 570311, Hainan Province, China

Hong-Fei Wu, Jin-Cai Wu, Zhen-Sheng Zhang, Jin-Fang Zheng, Yun-Fu Lv, Department of General Surgery, Hainan General Hospital, Haikou 570311, Hainan Province, China

Abstract BACKGROUND Hypersplenism associated with cirrhotic portal hypertension is a common condition often resulting from hepatitis B-related cirrhosis. However, the levels of immunoglobulin (Ig) and complement in patients with hypersplenism associated with cirrhotic portal hypertension remain unclear. This study was undertaken to determine the levels of Ig and complement in these patients, the relationship between these levels and Child-Pugh class and their clinical significance.AIM To investigate the antibody (Ig) and complement levels in patients with hypersplenism associated with cirrhotic portal hypertension and their clinical significance.METHODS Clinical data of 119 patients with hypersplenism associated with cirrhotic portal hypertension were statistically analyzed and compared with those of 128 control patients.RESULTS IgA and IgG levels in patients with hypersplenism were significantly higher than controls (P < 0.001). There was no significant difference in IgM between the two groups (P = 0.109). C3 and C4 levels in patients with hypersplenism were significantly lower than controls (P < 0.001). As liver function decreased, IgA and IgG levels increased (P < 0.001), and C3 and C4 levels decreased (P < 0.001).CONCLUSION Patients with hypersplenism associated with cirrhotic portal hypertension have significantly higher antibody (IgA and IgG) levels and significantly lower complement (C3 and C4) levels, which are both related to liver damage. Clinically, the administration of anti-hepatitis virus agents and protection of liver function should be strengthened.

Key Words: Hypersplenism associated with cirrhotic portal hypertension; Complement; Treatment; Hepatitis;B-immunoglobulin

INTRODUCTION

Hypersplenism associated with cirrhotic portal hypertension is a common condition often resulting from hepatitis B-related cirrhosis[1]. Hepatitis B is a chronic infectious disease caused by hepatitis B virus (HBV) infection[2]. Under normal circumstances, the immune system protects the body by defending against external invading pathogens, maintaining physiological balance and eliminating diseased cells through cellular and/or humoral immunity. An abnormal immune response, whether hyperactive (i.e.allergy) or hypoactive (i.e.immunodeficiency), can cause tissue damage and immunopathological reactions[3].

HBV infection is a global public health issue; in particular, China has a high prevalence of HBV[4]. The pathogenesis of HBV infection is not yet fully understood. Numerous studies have shown that the immunopathological response and the interaction between the virus and host cells are the main causes of liver cell damage[5]. The progression and outcome of HBV infection is therefore related to the host’s immune response. Immunosuppression or immune system disorder can cause HBV replication, leading to chronic infection, and then develop cirrhosis. Liver cirrhosis caused by any reason may lead to hypersplenism related to portal hypertension[6] and possibly liver cancer.

Antibodies are important effector molecules that mediate humoral immunity by binding to specific antigens. They are immunoglobulins (Ig) produced by plasma cells, which are differentiated from B cells and memory B cells in the immune system under antigen stimulation[7]. They are distributed in the serum, tissue fluid, exocrine fluid and on the surface of some cell membranes. They demonstrate antibody-dependent cell-mediated cytotoxicity and play a role in neutralization, opsonization and complement activation[8,9].

By combining different heavy and light chains, Igs form complete antibody molecules that can be classified into five types: IgG, IgM, IgA, IgD and IgE. IgG is the only antibody that can cross the placental barrier and is the main component of serum Igs[10]. It is the main antibody produced during the immune response and the “main force” to fight against infection; in fact, most antibody activity in the serum is related to IgG. It activates complement through the classical pathway and binds to Fc receptors on the surface of macrophages and natural killer cells to regulate antibody-dependent cellmediated cytotoxicity[11]. IgM accounts for 5%-10% of the total serum Ig pool. It is the first antibody to be produced during ontogeny[12] and to appear in the primary humoral immune response, serving as the “vanguard” for specific defense against infection. IgA is an exocrine Ig that participates in local mucosal immunity and plays an important role as the ”border guard” for local defense against infection. IgE is mainly present in the allergic response[13], and IgD is present only in trace amounts[14,15].

Complement proteins play vital roles in the immune response, affecting both innate and adaptive immunity, regulating the immune response at different stages and influencing the immunological function of antibodies. In particular, the complement protein C3 plays a critical role. The level of serum C3 is proportional to the total amount of complement, and the serum C3 and C4 levels provide a good estimate for the total serum complement level[16,17]. However, the levels of Ig and complement in patients with hypersplenism associated with cirrhotic portal hypertension remain unclear. This study was undertaken to determine the levels of Ig and complement in these patients, the relationship between these levels and Child-Pugh class and their clinical significance.

MATERIALS AND METHODS

Patients and methods

A total of 119 patients with hypersplenism were compared with a control group of 128 patients. All methods were performed in accordance with the relevant guidelines and regulations/Declaration of Helsinki. Informed consent was obtained from all patients.

The hypersplenism group was composed of hypersplenism caused by cirrhosis and portal hypertension. Patients with hypersplenism caused by non-cirrhotic portal hypertension, such as lymphoma, pulmonary tuberculosis, connective tissue and inflammatory diseases, were excluded. The 119 patients included 93 males and 26 females, with a male-to-female ratio of 3.6:1. Their ages ranged from 41 years to 82 years, with a mean of 51 years. Among them, 95 patients (80.0%) had hepatitis B cirrhosis, 13 (10.9%) had hepatitis C cirrhosis, 3 (2.5%) had biliary cirrhosis, and 8 (6.6%) had other types of cirrhosis. Liver cirrhosis and splenomegaly (as assessed by B-Mode ultrasound and computed tomography), mono- or multilineage peripheral cytopenias (as assessed by laboratory tests) and moderate or severe varices in the lower esophagus and gastric fundus (as assessed by computed tomography and endoscopy), were found in all patients.

Furthermore, all patients underwent surgical treatment. Specifically, 45 patients (37.8%) underwent hepatic lobectomy for concomitant liver cancer, 33 (27.7%) underwent devascularization of the lower esophagus and gastric fundus + splenectomy for massive gastrointestinal bleeding (≥ 1000 mL), 12 (10.1%) underwent splenectomy for splenomegaly in which the spleen extends beyond the midline of the abdomen or below the line joining the two anterior superior iliac spines-and reduced quality of life, 15 (12.6%) underwent splenectomy + portal-azygos disconnection for moderate or severe hypersplenism, 11 (9.3%) underwent splenectomy alone, and 3 (2.5%) underwent portacaval shunt alone. Liver tissue was collected during the operation and sent for pathological examination, which revealed cirrhosis.

The control group was composed of surgical patients without hypersplenism associated with cirrhotic portal hypertension. These patients had no history of hepatitis virus infection or cirrhosis caused by other reasons. The liver function was normal, and the spleen volume was not enlarged. The 128 control patients included 65 males and 63 females, with a male-to-female ratio of 1:1. Their ages ranged from 20 years to 93 years, with a mean of 49 years. Specifically, 49 patients with cholecystolithiasis and 9 with gallbladder polyps underwent laparoscopic cholecystectomy, 38 with choledocholithiasis underwent choledocholithotomy, 19 with inguinal hernia and femoral hernia underwent laparoscopic hernia repair, and 13 with nodular goiter underwent subtotal thyroidectomy.

Detection method

Ig, C3 and C4 were detected by turbidimetric inhibition immunoassay. Briefly, 2 mL of peripheral venous blood was drawn from the patient, placed in a dry test tube and sent to the hospital laboratory for routine detection.

Statistical analysis

Statistical analysis was performed using SPSS software v25.0 (IBM Corp., Armonk, NY, United States). Measurement data were expressed as (average of x ± standard deviation) and [mean (P25, P75)]. The t/z test and Wilcoxon rank sum test for two independent samples were used for comparison between groups.P< 0.05 orP< 0.001 were considered statistically significant.

RESULTS

Comparison of sex and age between the two groups

There were significantly more males than females in the hypersplenism group compared to controls (P< 0.05). There was no significant difference in age between the two groups (P> 0.05).

Comparison of Ig levels before treatment between the two groups

Compared with the control group, IgA and IgG levels were significantly higher in the hypersplenism group (Z= -6.61 and -7.16, respectively;P< 0.001). There was no significant difference in IgM levels between the two groups (Z= -1.60,P= 0.109) (Figure 1).

Comparison of complement levels between the two groups before treatment

Compared with the control group, C3 and C4 levels were significantly lower in the hypersplenism group (t/z = 4.28 and -6.65, respectively;P< 0.001) (Figure 2).

The relationship between Child-Pugh class and Ig and complement levels in patients with hypersplenism associated with cirrhotic portal hypertension

For comparison of IgA, there were significant differences between class A and B (Z= 3.773,P< 0.001) and class A and C (Z= 2.373,P= 0.018) but not between class B and C (Z= 0.190,P= 0.850). For comparison of IgG, there were significant differences between class A and C (t = 3.732,P< 0.001) and class B and C (t = 2.225,P= 0.032) but not between class A and B (t = 1.252,P= 0.213). There were no statistically significant differences between the IgM groups. For comparison of C3, there were significant differences between class A and B (t = 3.149,P= 0.002), and class A and C (t = 3.857,P< 0.001) but not between class B and C (t = 0.486,P= 0.630). For comparison of C4, there were significant differences between class A and B (Z= 3.364,P< 0.001) but not between class A and C (Z= 1.851,P= 0.064) nor class B and C (Z= 0.298,P= 0.765) (Figure 3).

Figure 1 Comparison of immunoglobulin levels (g/L) between the hypersplenism group and the control group. bP < 0.001. Ig: Immunoglobulin.

Figure 2 Comparison of complement levels (g/L) between the hypersplenism group and the control group. aP < 0.05; bP < 0.001.

Figure 3 Relationship between Child-Pugh class and immunoglobulin and complement levels. aP < 0.05; bP < 0.001. Ig: Immunoglobulin.

DISCUSSION

Based on B-Mode ultrasound and computed tomography findings, endoscopy revealed moderate-tosevere varices in the lower esophagus and gastric fundus. Liver tissue was collected during the operation and sent for pathological examination. These findings supported the diagnosis of cirrhotic portal hypertension. Dameshek[18] proposed four criteria for a diagnosis of hypersplenism: (1) Splenomegaly; (2) One or several types of cytopenia; (3) Bone marrow is normal or in hyperplastic state; and (4) Pathological changes of blood cells disappeared after splenectomy. The clinical manifestations of portal hypertension include splenomegaly, and for patients with hypersplenism, peripheral cytopenia should be present and blood counts should become normal after splenectomy[4]. The diagnosis of hypersplenism in cirrhotic portal hypertension is consistent with all patients[19].

Although there was a significant difference in sex composition between the two groups, there was no significant difference in age. Hence, there should be no age-related effect on the Ig and complement measurements between the hypersplenism patients and controls. IgA and IgG levels were significantly higher than controls, indicating that patients with hypersplenism associated with cirrhotic portal hypertension had elevated serum levels of the two dominant Igs. This phenomenon has gained the attention of clinicians[11] and has been repeatedly confirmed[20,21]. Elevated serum Ig levels are of great significance in clinical diagnosis[20] and are suggestive of liver damage.

In this study, hypersplenism patients with Child-Pugh class C had significantly higher IgA and IgG levels than those with class A or B, indicating that the liver function was inversely correlated with serum levels of the two main Igs. There was no significant difference in IgM among the Child-Pugh classes, which may be related to its low total amount in all groups. There are two reasons for the increased Ig levels in the class C patients. Namely, a large number of antibodies are produced to eliminate the virus, and cirrhosis caused by HBV results in liver cell dysfunction and a reduced ability to remove antibodies[22]. Further research is required to determine whether and to what extent enhanced splenic macrophage function is correlated with increased Ig levels in patients with hypersplenism associated with cirrhotic portal hypertension[23].

The significantly lower serum levels of complements C3 and C4 in patients with hypersplenism associated with cirrhotic portal hypertension are also related to liver function impairment. One possible explanation is the reduced ability of damaged liver cells to synthesize complements. Another possibility is the development of a portal systemic collateral circulation, allowing a large amount of endotoxin to enter the bloodstream, which simultaneously activates the classical and alternative pathways, resulting in a large amount of complements to be consumed[24] and a substantial reduction in C3 and C4 levels[25].

This study shows that increased liver function impairment corresponds to lower levels of C3 and C4. As a type of globulin with antibody activity in human serum or fluid, Igs are antimicrobial and antiviral and enhance phagocytosis. Moreover, they can kill or dissolve pathogenic microorganisms with the assistance of complements, which is an important defense function in anti-infection immunity. Therefore, understanding serum Ig levels and their relationship to liver function in patients with hypersplenism associated with cirrhotic portal hypertension is of great clinical significance for assessing the disease progression and strengthening liver-protective treatment.

CONCLUSION

Patients with hypersplenism associated with cirrhotic portal hypertension have significantly higher antibody (IgA and IgG) levels and significantly lower complement (C3 and C4) levels. The increase of antibodies and the decrease of complement are related to liver function damage. Clinically, the administration of anti-hepatitis virus agents and protection of liver function should be strengthened[26-28].

ARTICLE HIGHLIGHTS

Research background

The antibody and complement levels in patients with cirrhosis and hypersplenism due to portal hypertension are not clear, which affects the diagnosis and treatment to some extent.

Research motivation

There are no studies determining the levels of immunoglobulins (Ig) and complements in patients with hypersplenism due to cirrhosis and portal hypertension, which affects the diagnosis and treatment.

Research objectives

To investigate the antibody (Ig) and complement levels in patients with hypersplenism due to liver cirrhosis and portal hypertension and how to treat them.

Research methods

The levels of IgA, IgG, IgM, C3 and C4 were determined and compared in 119 patients with confirmed hypersplenism and 128 control patients.

Research results

The levels of IgA and IgG in the hypersplenism group were significantly higher than those in the control group (P< 0.001). The levels of C3 and C4 in the hypersplenism group were significantly lower than those in the control group (P< 0.001). The worse the liver function was, the higher the IgA and IgG levels were (P< 0.001) and the lower the C3 and C4 levels were (P< 0.001).

Research conclusions

Antibodies in patients with liver cirrhosis and portal hypertension and hypersplenism were significantly increased, while complements (C3 and C4) were significantly decreased. Both the increase of antibody and the decrease of complement are related to the damage of liver function.

Research perspectives

It is important to know the antibody (Ig) and complement levels of patients with hypersplenism due to cirrhosis and portal hypertension. Anti-hepatitis virus and liver function protection should be strengthened in treatment.

FOOTNOTES

Author contributions:Zhang K, Zeng M, Li YJ, Wu JC, Zheng JF and Lv YF contributed equally to this work; Lv YF was responsible for project design and thesis writing; Zhang K and Li YJ were responsible for implementation and statistical information; Wu JC, Zheng JF and Zeng M were responsible for data and statistical information collection; Wu HF and Zhang ZS participated in data collection and registration; all authors have read this article and consent to publication.

Supported byHainan Provincial Department of Science and Technology, Qiongke[2020]256.

Institutional review board statement:The patient data and research content submitted in this project comply with relevant laws and regulations. The study was approved for implementation by the Ethics Committee of Hainan General Hospital, approval No: Med Eth Re [2020] 086.

Conflict-of-interest statement:All authors report no relevant conflicts of interest for this article.

Data sharing statement:All data generated or analyzed during this study were included in this published article.

Open-Access:This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin:China

ORCID number:Yun-Fu Lv 0000-0003-0451-399X.

S-Editor:Xing YX

L-Editor:Filipodia

P-Editor:Xing YX